NasdaqGS - Nasdaq Real Time Price USD
Aardvark Therapeutics, Inc. (AARD)
11.92
+0.26
+(2.26%)
As of 10:30:48 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 3 |
| Avg. Estimate | -0.68 | -0.75 | -2.91 | -2.38 |
| Low Estimate | -0.82 | -0.9 | -3.37 | -2.52 |
| High Estimate | -0.54 | -0.61 | -2.46 | -2.26 |
| Year Ago EPS | -- | -- | -5.15 | -2.91 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | 1.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 3M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2024 | 3/31/2025 |
|---|---|---|
| EPS Est. | -0.2 | -0.7 |
| EPS Actual | -- | -0.71 |
| Difference | -- | -0.01 |
| Surprise % | -- | -0.71% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.68 | -0.75 | -2.91 | -2.38 |
| 7 Days Ago | -0.74 | -0.77 | -2.54 | -2.41 |
| 30 Days Ago | -0.74 | -0.77 | -2.54 | -2.41 |
| 60 Days Ago | -0.74 | -0.77 | -2.58 | -2.54 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AARD | -- | -- | 43.40% | 18.47% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 5/15/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 4/1/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2025 |
| Maintains | B of A Securities: Buy to Buy | 3/27/2025 |
| Initiated | RBC Capital: Outperform | 3/10/2025 |
| Initiated | Cantor Fitzgerald: Overweight | 3/10/2025 |
Related Tickers
MAZE Maze Therapeutics, Inc.
13.74
+0.55%
SION Sionna Therapeutics, Inc.
15.26
+5.40%
MTSR Metsera, Inc.
28.51
-2.87%
ELVN Enliven Therapeutics, Inc.
21.83
-0.16%
ENTA Enanta Pharmaceuticals, Inc.
7.27
+1.11%
CHRO Channel Therapeutics Corporation
1.0500
+0.96%
CELUW Celularity Inc.
0.0409
-18.20%
CNTA Centessa Pharmaceuticals plc
13.18
-1.35%
NUVL Nuvalent, Inc.
78.15
-0.04%
MBX MBX Biosciences, Inc.
14.33
+4.87%